Author: Editor

普通话肺癌视频库-NSCLC 3期放化疗后的巩固免疫治疗 Dr. Jenni Li joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video Library, for our mandarin speaking community. In this video, Dr. Li shares information on which stage 3 non small cell lung cancer patients should receive consolidation immunotherapy after chemoradiation. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Dr. Jenni Li joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video Library, for our mandarin speaking community. In this video, Dr. Li shares information on the role of immunotherapy for unresectable stage 3 non small cell lung cancer. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Professor Alessandro Zerbi of the Humanitas Research Hospital Para-aortic Lymphnodes Removal During Upfront Pancreaticoduodenectomy (PALN). Summary Brief: The only curative alternative for patients affected by pancreatic ductal adenocarcinoma (PDAC) is pancreaticoduodenectomy (PD) combined with lymphadenectomy. In 2014, “normal lymphadenectomy” was established by the International Study Group on Pancreatic Surgery (ISGPS), which is mandatory for PDAC during PD. Lymphadenectomy may include the elimination of the nodes of the hepatoduodenal ligament (stations 5, 6, 12b1, 12b2, 12c, Japanese Pancreas Society classification), the nodes of the hepatic artery (station 8a), the posterior surface of the pancreatic head (stations 13a and 13b), the upper…

Maxime Meylan, PhD of the Centre de Recherche des Cordeliers explains the ESMO Virtual Congress 2020: Clear Cell Renal Cell Carcinoma Immune Classification Enhances the Predictive Value of T Effector and Angiogenesis Signatures in Response to Nivolumab abstract.A real-world phase 2 multicenter analysis of nivolumab in metastatic clear cell renal cell carcinoma (ccRCC) was the NIVOREN GETUG-AFU26 clinical trial. Compared with the randomized phase 3 CheckMate 025 trial comparing nivolumab to everolimus, published in 2015, the patient results of this study were favorable. A translational program was launched in the NIVOREN trial to analyze molecular features associated with the response…

Philadelphia, PA (October 12, 2020) – Oncoceutics, Inc. announced that the European Patent Office has issued a Decision to Grant for a Composition of Matter patent for ONC212, one of the company’s next-generation oncology drug candidates. The company also announced that a pending ONC201 patent has been granted for Mexico and that it received a Certificate of Grant for a Composition of Matter patent for ONC201 in Japan.These new patents, combined with a number of patents issued since the beginning of 2020, including, among others, patents for Composition of Matter for ONC201 in China and for ONC206 in Australia and…

Andrzej Jakubowiak, MD, Ph.D. of the University of Chicago Comprehensive Cancer Center speaks on the ASCO 2020 abstract Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011) Context: Orva-cel is a BCMA-directed, investigational CAR T cell product with a completely human binder. In the EVOLVE phase 1 analysis, more than 100 pts were treated. There were previously registered pts treated at 50 and 150 x 106 CAR+ T cells (Mailankody ASH 2018 # 957). Results of higher dose levels (DLs) in…

Robert Coleman, MD, FACOG, FACS, Chief Scientific Officer U.S. Oncology Research discusses Elevation Oncology and US Oncology Research Announce Collaboration to Expand Genomic Testing of Solid Tumors and Local Site Activation in Support of the Phase 2 CRESTONE Study.US Oncology Research serves approximately 60 research sites and more than 165 locations, managing about 400 active trials at any given time.NEW YORK and THE WOODLANDS, Texas, Sept. 30, 2020 /PRNewswire/ — Elevation Oncology, a biopharmaceutical clinical-stage company focusing on the production of precise medicines for genomically identified cancer patients, and US Oncology Research, one of the largest community-based oncology site management…

Paul G. Richardson, MD of Dana-Farber Cancer Institute explains the abstract entitled First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).Explanation:The novel Cereblon E3 ligase modulator (CELMoD) agent CC-92480 is designed for the rapid, maximum degradation of Ikaros and Aiolos. In vitro, MM cell lines, including those resistant to lenalidomide (LEN) and pomalidomide (POM), have increased antiproliferative and tumoricidal activity, with high immune stimulatory activity.Methodology:Maximum tolerated dose (MTD), recommended phase 2 dose, protection, tolerability, and pharmacokinetics of CC-92480 + DEX in heavily pretreated RRMM pts were evaluated…

Alexander Stratigos, M.D., Professor of Dermatology/Or Investigator of the University of Athens Medical School at Andreas Sygros Hospital explains the ESMO 2020 Abstract on Primary analysis of phase II results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to hedgehog inhibitors (HHIs). Abstract LBA47  Context There is no approved post-HHI therapeutic option for LaBCC pts. Cemiplimab, a PD-1 antibody, is a proven drug approved for the treatment of advanced cutaneous squamous cell carcinoma (CSCC) in patients who are not candidates for curative surgery or radiation therapy. Both BCC and CSCC,…

Para este año, además de nuestra videoteca de cáncer de pulmón producida en español para nuestra comunidad latina, el Dr. Luis Raez nos brinda información actualizada. En este video, el Dr. Raez discute las terapias dirigidas para NSCLC (NTRK 1-3). Para más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum. ***** For this years addition to our Lung Cancer Video Library produced in Spanish for our Latino Community, Dr. Luis Raez provides us with up to date information. In this video, Dr. Raez discusses targeted therapies for NSCLC (NTRK 1-3). For more, please visit http://cancerGRACE.org/. To join the…

Para este año, además de nuestra videoteca de cáncer de pulmón producida en español para nuestra comunidad latina, el Dr. Luis Raez nos brinda información actualizada. En este video, el Dr. Raez analiza las terapias dirigidas para el NSCLC (MET y BRAFv600). Para más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum. ***** For this years addition to our Lung Cancer Video Library produced in Spanish for our Latino Community, Dr. Luis Raez provides us with up to date information. In this video, Dr. Raez discusses targeted therapies for NSCLC (MET and BRAFv600). For more, please visit http://cancerGRACE.org/.…

Para este año, además de nuestra videoteca de cáncer de pulmón producida en español para nuestra comunidad latina, el Dr. Luis Raez nos brinda información actualizada. En este video, el Dr. Raez analiza las nuevas terapias dirigidas para el NSCLC a la espera de aprobación (RET – Loxo 292 y Blu667) Para más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum. ***** For this years addition to our Lung Cancer Video Library produced in Spanish for our Latino Community, Dr. Luis Raez provides us with up to date information. In this video, Dr. Raez discusses new targeted therapies…

Para estos videos adicionales a nuestra Biblioteca de videos sobre el cáncer de pulmón producidos en español para nuestra comunidad latina, la Dra. Gelenis Domingo nos brinda información actualizada. En este video, el Dr. Domingo analiza biopsias líquidas y cáncer de pulmón. Para más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum. ***** For these additional videos to our Lung Cancer Video Library produced in Spanish for our Latino Community, Dr. Gelenis Domingo provides us with up to date information. In this video, Dr. Domingo discusses liquid biopsies and lung cancer. For more, please visit http://cancerGRACE.org/. To join…

Para estos videos adicionales a nuestra Biblioteca de videos sobre el cáncer de pulmón producidos en español para nuestra comunidad latina, la Dra. Gelenis Domingo nos brinda información actualizada. En este video, el Dr. Domingo analiza la inmunoterapia del cáncer de pulmón de células pequeñas y la terapia dirigida. Para más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum. ***** For these additional videos to our Lung Cancer Video Library produced in Spanish for our Latino Community, Dr. Gelenis Domingo provides us with up to date information. In this video, Dr. Domingo discusses small cell lung cancer immunotherapy…

Para estos videos adicionales a nuestra Biblioteca de videos sobre el cáncer de pulmón producidos en español para nuestra comunidad latina, la Dra. Gelenis Domingo nos brinda información actualizada. En este video, el Dr. Domingo analiza la terapia dirigida para NSCLC (EGFR). Para más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum. ***** For these additional videos to our Lung Cancer Video Library produced in Spanish for our Latino Community, Dr. Gelenis Domingo provides us with up to date information. In this video, Dr. Domingo discusses targeted therapy for NSCLC (EGFR). For more, please visit http://cancerGRACE.org/. To join…

Para estos videos adicionales a nuestra Biblioteca de videos sobre el cáncer de pulmón, producida en español para nuestra comunidad latina, la Dra. Gelenis Domingo nos brinda información más actualizada. En este video, el Dr. Domingo analiza la terapia dirigida para NSCLC (ALK y ROs-1). Para más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum. ***** For these additional videos to our Lung Cancer Video Library, produced in Spanish for our Latino Community, Dr. Gelenis Domingo provides us with more up to date information. In this video, Dr. Domingo discusses targeted therapy for NSCLC (ALK and ROs-1). For…

Para estos videos adicionales a nuestra Biblioteca de videos sobre el cáncer de pulmón producidos en español para nuestra comunidad latina, la Dra. Gelenis Domingo nos brinda información actualizada. En este video, el Dr. Domingo analiza la necesidad del diagnóstico molecular en el cáncer de pulmón (pruebas NGS y PD-L1). Para más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum. ***** For these additional videos to our Lung Cancer Video Library produced in Spanish for our Latino Community, Dr. Gelenis Domingo provides us with up to date information. In this video, Dr. Domingo discusses the need of molecular…

Para este año, además de nuestra videoteca de cáncer de pulmón producida en español para nuestra comunidad latina, el Dr. Luis Raez nos brinda información actualizada. En este video, el Dr. Raez analiza la inmunoterapia para el cáncer de pulmón no microcítico. Para más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum. ***** For this years addition to our Lung Cancer Video Library produced in Spanish for our Latino Community, Dr. Luis Raez provides us with up to date information. In this video, Dr. Raez discusses immunotherapy for non small cell lung cancer. For more, please visit http://cancerGRACE.org/.…

Para este año, además de nuestra videoteca de cáncer de pulmón producida en español para nuestra comunidad latina, el Dr. Luis Raez nos brinda información actualizada. En este video, el Dr. Raez habla sobre la detección del cáncer de pulmón. Para más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum. ******* For this years addition to our Lung Cancer Video Library produced in Spanish for our Latino Community, Dr. Luis Raez provides us with up to date information. In this video, Dr. Raez discusses Lung Cancer Screening. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For the GRACE Blood Cancer Video Library, Dr. Joshua Brody, Assistant Professor of Medicine, Hematology and Medical Oncology and Director of the Lymphoma Immunotherapy Program at the Icahn School of Medicine at Mount Sinai Hospital joins us to discuss updates from ASH 2019. For this video, Dr. Brody shares information on Mantle Cell Lymphoma, and the exciting outcomes from CAR-T Cell therapy trials. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For the GRACE Blood Cancer Video Library, Dr. Marco Ruiz, Medical Oncologist in Hematologic Cancers specializing in leukemia, lymphoma, Myelodysplastic syndrome, myelofibrosis, HIV related malignancies, stem cell transplants, geriatric oncology, palliative medicine at the Miami Cancer Institute in Miami, Florida joins us to discuss updates the updates in treatments for blood cancers. For this video, he discusses the the role of bone marrow transplantation and other therapies for blood cancers. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For the GRACE Blood Cancer Video Library, Dr. Marco Ruiz, Medical Oncologist in Hematologic Cancers specializing in leukemia, lymphoma, Myelodysplastic syndrome, myelofibrosis, HIV related malignancies, stem cell transplants, geriatric oncology, palliative medicine at the Miami Cancer Institute in Miami, Florida joins us to discuss updates the updates in treatments for blood cancers. For this video, he discusses the diagnosis & management of blood cancers. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For the GRACE Blood Cancer Video Library, Dr. Marco Ruiz, Medical Oncologist in Hematologic Cancers specializing in leukemia, lymphoma, Myelodysplastic syndrome, myelofibrosis, HIV related malignancies, stem cell transplants, geriatric oncology, palliative medicine at the Miami Cancer Institute in Miami, Florida joins us to discuss updates the updates in treatments for blood cancers. For this video, he shares information on the prevalence and epidemiology of blood cancers. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For the GRACE Blood Cancer Video Library, Dr. Joshua Brody, Assistant Professor of Medicine, Hematology and Medical Oncology and Director of the Lymphoma Immunotherapy Program at the Icahn School of Medicine at Mount Sinai Hospital joins us to discuss updates from ASH 2019. For this video, he shares information on CLL (Chronic Lymphocytic Leukemia) and a new generation of BTK Inhibitors For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For the GRACE Blood Cancer Video Library, Dr. Joshua Brody, Assistant Professor of Medicine, Hematology and Medical Oncology and Director of the Lymphoma Immunotherapy Program at the Icahn School of Medicine at Mount Sinai Hospital joins us to discuss updates from ASH 2019. For this video, he shares information on Bi-specific Therapy and new treatments for diffuse large B-Cell lymphoma (DLBCL) and follicular lymphoma. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this video Dr.Matthew Gubens discusses targeted therapies in non small cell lung cancer. What are the leading treatment options for patients with low or negative tumor PD-L1 expression and advanced squamous NSCLC today? For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this video Dr.Matthew Gubens discusses non small cell lung cancer, and immunotherapy. For a frail patient with advanced NSCLC, can immunotherapy help as a treatment option? For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this video Dr.Matthew Gubens discusses non small cell lung cancer, and tumor mutational burden. At this time could TMB be helpful in non small cell lung cancer management? For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this video Dr. Millie Das discusses Immunotherapy in non small cell lung cancer., and the current role of immunotherapy for unresectable stage lll NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this series of the GRACE Lung Cancer Video Library, Dr. Millie Das joined us to discuss targeted therapies in non small cell lung cancer (NSCLC) and what the current leading treatment options are for patients with low or negative tumor PDL1 expression and advanced non squamous NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For the GRACE Lung Cancer Video Library, Dr. Millie Das joined us to discuss Immunotherapy in non small cell lung cancer (NSCLC), and whether immunotherapy has activity in malignant pleural mesothelioma. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Prof. Jean Bourhis, Department Head of Radio-Oncology at the University Hospital of Lausanne and Lead Investigator of Centre Hospitalier Universitaire Vaudois explains the ESMO 2020 Abstract Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 “PembroRad” randomized trial. Abstract LBA388  Context This new combination was tested in a randomized trial against the well-established standard of care (SOC) cetuximab-RT in LA-HNSCC on the basis of the hypothesis of the possible synergistic effect of anti-PD1 pembrolizumab when combined with RT. Methodology In this phase II randomized trial, patients with…

Aditya Bardia, MD, MPH of Massachusetts General Hospital discusses the Natera Announces Collaboration with Massachusetts General Hospital for a Prospective Randomized Clinical Trial in Early Stage Breast Cancer. SAN CARLOS, Calif., Aug. 27, 2020/PRNewswire/ — Natera, Inc. ( NASDAQ: NTRA), a pioneer and global leader in cell-free DNA, today announced a joint agreement with the Mass General Cancer Center (MGCC) of Massachusetts General Hospital, connected to the Phase II randomized clinical trial of Ribociclib (Kisqali ®), a CDK4/6 inhibitor, for the treatment of ER-pository multi-center treatment. LEADER (Part II) will randomize patients with localized postmenopausal breast cancer as proof of…

Aditya Bardia, MD, MPH of Dana-Farber Cancer Institute speaks about ESMO 20 ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC).Abstract LBA17ContextStandard of care (SOC) chemotherapy in pts with pretreated mTNBC is associated with poor objective response rates (ORRs) and limited median progression-free survival (mPFS). SG (TRODELVYTM) is a first-in-class antibody-drug conjugate (ADC) consisting of an anti-Trop-2 antibody attached to the irinotecan active metabolite, SN-38, through a specific hydrolysable linker that allows intracellular and tumor microenvironment (bystander effect) release of SN-38. SG…

Andrea B. Apolo, MD of NIH National Cancer Institute speaks about the ESMO 2020 abstract New First-Line Treatment Option For Metastatic Kidney Cancer, According To Results Of Phase 3 Study.LUGANO, Switzerland-For patients with metastatic kidney cancer, the findings of the phase 3 CheckMate 9ER trial have provided a potential first-line treatment choice. At ESMO 2020, the late break results are discussed. (1) The research took two second-line monotherapy medications, nivolumab, and cabozantinib, and merged them for use as a first-line standard-of-care drug, sunitinib. The combination was superior for progression-free survival, overall survival, and response rate compared to sunitinib. In various…

Angel A. Rodriguez, MD, Oncology Medical Director of Natera speaks about Natera Announces Collaboration with Massachusetts General Hospital for a Prospective Randomized Clinical Trial in Early Stage Breast Cancer. SAN CARLOS, Calif., Aug. 27, 2020/PRNewswire/ — Natera, Inc. ( NASDAQ: NTRA), a pioneer and global leader in cell-free DNA, today announced a joint agreement with the Mass General Cancer Center (MGCC) of Massachusetts General Hospital, connected to the Phase II randomized clinical trial of Ribociclib (Kisqali ®), a CDK4/6 inhibitor, for the treatment of ER-pository multi-center treatment. LEADER (Part II) will randomize patients with localized postmenopausal breast cancer as proof…

Roy S Herbst, MD, Ph.D. of the Yale School of Medicine and Yale Cancer Center discusses ESMO 2020 abstract Yale Trial Validates Immunotherapy Treatment for Non-Small Cell Lung Cancer.New Haven, Conn. Atezolizumab, the immunotherapy drug, improves survival over standard survival.For several patients with newly diagnosed non-small cell lung cancer ( NSCLC), chemotherapy,A new study led by researchers from the Yale Cancer Center (YCC) shows that. The conclusions, from aStep 3 global randomized clinical trial, published today in the New England Journal ofMedicine, assistance with the U.S. The approval of the medication by the Food and Drug Administration for this in…

Timothy A. Yap, MD of MD Anderson discusses ESMO 2020 Poster: Rucaparib + Sacituzumab Govitecan: Initial Data From the Phase 1b/2 SEASTAR Study (NCT03992131) SEASTAR study presented at ESMO. SUMMARY  Initial promising signs of antitumor activity were seen in patients with advanced solid tumors (n=6) with the combination of rucaparib + sacituzumab govitecan, including patients with prior polymerase inhibitor exposure (ADP-ribose) and without deleterious homologous recombination repair gene mutation. * Despite premature toxicity, all 6 patients * Continued treatment with successful treatment of emergent adverse reactions * Controlled with dose adjustment and/or help for the growth factor * Further consideration…

Dr. Zeynep Zengin, post-doctoral fellow at City of Hope discusses the ESMO Virtual Congress 2020: Assessment of Circulating Cell-Free Tumor DNA in 847 Patients with metastatic renal cell carcinoma (mRCC) and concordance with tissue-based testing.(UroToday.com) For patients undergoing systemic therapy for metastatic renal cell carcinoma (mRCC), biomarkers need to be identified to guide initial treatment decisions and to track treatment response. A non-invasive approach to determining tumor-level genetic modifications is the evaluation of circulating cell-free tumor DNA (ctDNA). Previously, ctDNA profiles have been shown to develop along with advanced kidney cancer treatment. It is important to understand the concordance of…

Professor Ray McDermott of St. Vincent University Hospital and Tallaght Hospital, Ireland discusses ESMO – Survival benefits of larotrectinib in an integrated dataset of patients with TRK fusion cancer. BACKGROUND Fusions of the neurotrophic tyrosine receptor kinase (NTRK) gene encode chimeric fusion. In a wide range of adult and pediatric tumors, tropomyosin receptor kinase (TRK) proteins, which are constitutively active and act as oncogenic motors. In different paediatric and adult tumour types, NTRK gene fusions have been reported, with an average incidence of 1 percent in all solid tumour types. They occur more commonly in such rare tumors, such as…

Professor Ray McDermott of St. Vincent University Hospital and Tallaght Hospital, Ireland explains the ESMO poster DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801). A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.BackgroundLuteinizing hormone-releasing hormone equivalent (LHRHA) radiation therapy (RT) plus androgen deprivation therapy (ADT) is the standard of treatment for men with very high-risk localized prostate cancer (PC) or with very high-risk features and chronic radical prostatectomy (RP) PSA. Despite this, incurable distant metastases in 15 percent of males with very high-risk features…

Peter R. Galle, MD of University Medical Center Mainz discusses his ESMO 2020 abstract – Updated results of a phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC). Background REG is an inhibitor of tyrosine kinase with immunomodulatory activity and PEMBRO is a monoclonal anti-PD-1 antibody. We have planned a phase Ib analysis of REG plus PEMBRO for first-line treatment of advanced HCC, based on possible synergistic effects. Methodology This is a dose-finding, continuing research of patients (pts) who have not had previous systemic therapy. In the first cohort, for 3 weeks…

W. Michael Korn, MD, CMO of Caris Life Sciences discusses their abstract – Caris Life Sciences Presented New Ovarian Cancer Research at ESMO Virtual Congress 2020IRVING, Texas, Sept. 15, 2020 /PRNewswire/ — Caris Life Sciences ®, a leading molecular science innovator focused on achieving the promise of precision medicine, today revealed findings from a study that may shed new light on patients with KRAS-mutated epithelial ovarian carcinoma (EOC) on their care path. These results, presented at the Virtual Congress 2020 of the European Society for Medical Oncology (ESMO), illustrate an unmet need for this patient population and indicate that targeted…

Jacob J. Adashek, DO of the Moffitt Cancer Center explains the ESMO 2020 Abstract – Personalized molecularly matched therapies for carcinomas of unknown primary is associated with improved outcomes. Context CUP accounts for 2-5 percent of the world’s overall cancer diagnoses and represents a Heterogeneous cancer community. Combination chemotherapy with modest reaction rates is the preferred treatment. (20 percent-40 percent). The median overall survival remains low (6-15 months), however. Empirical treatments have been performed (e.g. carboplatin / paclitaxel, cisplatin / gemcitabine). Centered on tissue-of-origin gene expression compared to tissue-specific therapies Profiling; There was no clinical advantage in randomized trials. While…

Roy S Herbst, MD, Ph.D. of Yale Cancer Center explains the ESMO abstract – Yale Cancer Center Study Reinforces Benefit Using Targeted Therapy for Early Stage NSCLC.New Haven, Conn.-According to revised findings led by Yale Cancer Center researchers, the treatment of osimertinib with targeted therapy following surgery appears to be important. In patients with early-stage, non-small cell lung cancer ( NSCLC) with epidermal growth factor receptor (EGFR) gene mutations, disease-free survival (DFS) is increased.The advantage of treatment with osimertinib shown in the ADAURA trial earlier this year was such that the independent data monitoring committee recommended the early unblinding of…

Ana Maria Arance Fernandez, MD of Hospital Clínic de Barcelona, Barcelona, Spain speaks on her ESMO abstract – LBA44 – Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004. Context Identification of safe and reliable MEL treatment options that have advanced towards anti-PD-1-based treatment A major unmet need is counseling. The single-arm, open-label, step 2 LEAP-004 analysis The combination of len (multikinase inhibitor) and pembro (anti-PD-1) is evaluated by (NCT03776136) in Such a nation. Methodology Qualified pts had unresectable stage III-IV MEL, PD confirmed by iRECIST within 12…

Alexander Eggermont, MD of Gustave Roussy Cancer Campus Grand Paris and University Paris-Saclay explains the ESMO 2020 abstract LBA46 – Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Final results regarding distant metastasis-free survival from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial. Context A randomized phase III, double-blind EORTC 1325 / KEYNOTE-054 study was performed to test pembrolizumab versus placebo in patients (pts) with resected stage III high-risk melanoma. Pembrolizumab enhanced recurrence-free survival (RFS) (hazard ratio [HR] 0.57, P<0.0001) relative to placebo at a 1.25-year (yr) median follow-up (Eggermont, NEJM 2018). This resulted in EMA and…

Zarnie Lwin, MD Royal Brisbane, and Women’s Hospital, University of Queensland discusses the ESMO abstract LBA41 – LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours. Context In early-phase studies, Len (antiangiogenic multiple receptor tyrosine kinase inhibitor) + pembro (anti-PD-1 agent) showed promising clinical results across several cancers and is FDA-approved for pts with previously treated advanced endometrial cancer that is not MSI-H or mismatch repair-deficient that are ineligible for curative / radiation surgery. The first findings of the phase 2 LEAP-005 study (NCT03797326) evaluating the efficacy and protection of…

John Bridgewater, MD, Ph.D., Medical Oncologist discusses ESMO abstracts Efficacy and Safety of Futibatinib in Intrahepatic Cholangiocarcinoma (iCCA) Harboring FGFR2 Fusions/Other Rearrangements: Subgroup Analyses of a Phase 2 Study (FOENIX-CCA2) and Quality of Life Outcomes With Futibatinib Treatment in FOENIX-CCA2, a Phase 2 Study in Patients With Intrahepatic Cholangiocarcinoma Harboring FGFR2 Gene Fusions/Rearrangements. 1 – Efficacy and Safety of Futibatinib in Intrahepatic Cholangiocarcinoma (iCCA) Harboring FGFR2 Fusions/Other Rearrangements: Subgroup Analyses of a Phase 2 Study (FOENIX-CCA2) Context FGFR2 fusions occur with iCCA and tumor suppressor computations in 10-20 percent of pts.  There may be prognostic genes. An analysis of futibatinib…

Dr. Neal Shore MD, FACS, CPI, of the Atlantic Urology Clinics and Director at the Carolina Urologic Research Center, discusses Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide and ESMO abstract tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase 3 ARAMIS trial.Prostate Nonmetastatic, Castration-Resistant Darolutamide Cancer and SurvivalBACKGROUNDDarolutamide is an inhibitor of the androgen receptor that is structurally distinct and approved for the treatment of non-metastatic, castration-resistant prostate cancer. The median metastasis-free survival was substantially longer with darolutamide (40.4 months) than with placebo (18.4 months) in the expected primary analysis…